TELIX Pharmaceuticals Ltd (TLX) - Total Liabilities

Latest as of June 2025: AU$768.01 Million AUD ≈ $543.42 Million USD

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has total liabilities worth AU$768.01 Million AUD (≈ $543.42 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TELIX Pharmaceuticals Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

TELIX Pharmaceuticals Ltd - Total Liabilities Trend (2000–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TELIX Pharmaceuticals Ltd balance sheet assets.

TELIX Pharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Willscot Mobile Mini Holdings Corp A NASDAQ:WSC	USA	$4.95 Billion
Acter Co Ltd TWO:5536	Taiwan	NT$25.34 Billion
Guangdong Provincial Expressway Development Co Ltd SHE:000429	China	CN¥10.18 Billion
SEB SA PA:SK	France	€6.13 Billion
Scotts Miracle-Gro Company NYSE:SMG	USA	$3.70 Billion
Proya Cosmetics Co Ltd Class A SHG:603605	China	CN¥2.80 Billion
KENON HLDGS LTD F:76N	Germany	€2.20 Billion
Netwealth Group Ltd AU:NWL	Australia	AU$156.90 Million

Liability Composition Analysis (2000–2024)

This chart breaks down TELIX Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of TELIX Pharmaceuticals Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.82	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.65	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how TELIX Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for TELIX Pharmaceuticals Ltd (2000–2024)

The table below shows the annual total liabilities of TELIX Pharmaceuticals Ltd from 2000 to 2024.

Year	Total Liabilities	Change
2024-12-31	AU$948.22 Million ≈ $670.92 Million	+280.21%
2023-12-31	AU$249.39 Million ≈ $176.46 Million	+39.77%
2022-12-31	AU$178.44 Million ≈ $126.25 Million	+68.06%
2021-12-31	AU$106.17 Million ≈ $75.12 Million	+34.73%
2020-12-31	AU$78.81 Million ≈ $55.76 Million	+147.22%
2019-12-31	AU$31.88 Million ≈ $22.56 Million	+33.92%
2018-12-31	AU$23.80 Million ≈ $16.84 Million	+1221.74%
2017-12-31	AU$1.80 Million ≈ $1.27 Million	+411.63%
2000-12-31	AU$352.00K ≈ $249.06K	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$4.20 Billion

AU$5.94 Billion AUD

Market Cap Rank

#4665 Global

#114 in Australia

Share Price

AU$17.75

Change (1 day)

+8.63%

52-Week Range

AU$8.63 - AU$17.75

All Time High

AU$31.14